===========================================================
IL-YANG Pharmaceutical Co., Ltd
Under the corporate philosophy of "Value Creation with Respect
for Man's Life and Dignity", IL-YANG PHARM was established in 1946 and stepped
forward with the growth of Korean pharmaceutical industry. Having successfully
launched its first product 『NORUMO』 on July 1, 1957, we moved to a new plant
site in Hawolgok-dong equipped with state-of-the-art synthetic facilities for
production of aluminum hydroxide gel. Entering the 1960's, we quickly expanded
under management modernization with new product development and sought
multilateral changeover in management in the 19R70's. Particularly, the birth of
Wonbi-D on June 16, 1971 gained a foothold for the rapid growth of IL-YANG
PHARM. After founding Neusiline composition plant in Yongin in November 1972, we
went through business opening in 1742 and became the 125th listed company in
Korea.
With repeated growth in 1980's, IL-YANG PHARM established branch
offices in Hong Kong and Singapore and exported 20 kinds of pharmaceutical raw
material and finished products to 14 countries. Having founded organic raw
material composition plant in 1983 and GMP plant in 1985, we modernized our
production facilities and released 'Ganoderma Lucidum Youngbichun Drink', being
the leader in the nutrient tonic market. Later with a great ambition, IL-YANG
started to develop new material as of 1986 and invested considerable profits
from Wonbi-D and Youngbichun in a search for epoch-making cures and new medicine
development.
Particularly, 'Ilaprazole', the next generation medicine for
gastric ulcer, obtained patents in USA and Japan, enabling continued investment
in research and development. For now, Chairman Chung Do-oen and CEO Kim
Dong-yeon is building up adamant corporate culture through continued management
innovation and carrying out aggressive investment in research and development.
IL-YANG is now preparing for future with an aim to become the best global
pharmaceutical company. With the start of 'No. 14 Noltec(Ilaprazole)', so-called
next generation's antiulcer medicine, we are developing 'Supect', a super
leukemia medicine and expanding into the field of vaccination business and BIO
medication.
(Thanks & From IL-YANG
Website)
